Pakistan Medical Devices Rules 2017 (MDR 2017): The Full-Chain Instrument

1. Key takeaways

The operating regulation for medical devices in Pakistan is the Medical Devices Rules, 2017 (Medical Devices Rules, 2017, abbreviated MDR 2017), made by DRAP under s.23 of the DRAP Act, 2012 and gazetted on 16 January 2018. It is a “full-chain” instrument, covering classification, enlistment, registration, establishment licensing, conformity assessment, labelling, advertising and post-market surveillance. Because the same instrument carries all of these subjects, its provisions interact: a definition in one rule feeds a form in another, and a schedule supplies the lists that the body of the rules refers to. Anyone working with MDR 2017 therefore needs to read it as one connected machine rather than as a set of independent chapters, and needs to track the amendment orders that keep adjusting that machine’s moving parts.

• MDR 2017 is a single set of rules governing the entire device lifecycle in Pakistan.
• Rule 13 creates two statutory pathways: enlistment and registration.
• Rule 14 governs applicants, forms, accompanying materials and return cases.
• Rule 15 governs issuance, the 5-year certificate validity and reasoned rejection in writing.
• Amendment orders (S.R.O.s) revise forms, definitions and fees at a high frequency.

2. Legal basis

The table below lists the principal provisions of MDR 2017 that a Pakistan dossier will touch, together with the amendment orders that have modified them. The list is the working map of the instrument: every procedural question raised during a project — which form, which fee, which validity period, which labelling obligation — should be answerable by pointing at one of these rows.

3. Expert insights

Insight 1: One set of rules governing the whole chain means there is no buffer between obligations. If the classification is wrong, the enlistment or registration form is wrong. If the establishment licence expires, the product certificate cannot get the goods through customs even while it remains valid. If the label does not match the approved version, the consignment is stopped at clearance. The stages are validated in series, not reviewed in parallel. A weakness anywhere in the chain surfaces downstream, often months after the original error was made, which is why the cheapest place to fix a chain defect is always at the classification and licensing stage rather than at the border. The practical lesson for project planning is that no stage can be treated as independently complete: each stage inherits the correctness of the one before it, and a schedule that optimises stages in isolation will still fail as a whole.

Insight 2: Rule 13 writes “enlistment” and “registration” as two statutory types, and this is Pakistan’s largest institutional difference from other markets. Most markets have only one pathway, registration. Pakistan explicitly splits Class A into enlistment and places Class B, C and D under registration. The distinction is not cosmetic: it changes the form, the depth of the review and the evidence expectations, and translations or summaries that blur the two terms mislead applicants about what Class A actually requires. Mislabelling an enlistment as a registration also creates problems downstream, because import documentation, certificate numbers and renewal planning all differ between the two routes.

Insight 3: The amendment orders (S.R.O.s) are dense and strike directly at operational detail. S.R.O. 430(I)/2022 amended the Form 6A / 7A forms themselves. S.R.O. 559(I)/2022 added definitions for refurbished devices and a donation channel, deleted Rule 25, and replaced Rule 27. S.R.O. 1399(I)/2025 changed the fees. These are amendments that take direct effect at the operational level, not principled declarations. A team that monitors only the parent rules will miss every one of these changes, so the S.R.O. feed must be tracked as closely as the rules text itself. In practice this means the gazette, not rumour, is the operating source: when a client asks what changed this year, the answer must come from the text of the S.R.O., not from secondary summaries.

4. Practical recommendations

• GRZAN maintains a mapping table of the rule body, the schedules and the amendment orders, which travels with every project.
• The body of the rules governs pathways; the schedules govern lists (Schedule B governs product grouping, Schedule C governs fees); the amendment orders govern the current positions.
• Before each submission we accept only the latest version of these three layers and never reuse historical templates.
• Form versions are checked against the amendment order that last revised them, so no dossier is filed on a superseded form.
• Fee quotations are always tied to the Schedule C position in force at filing time.
• Where a subject spans both the rule body and a schedule, both are cited together, so the reader sees the pathway and the list in one reference.
• A change log of the S.R.O.s relevant to each project is kept alongside the mapping table, so the team can state at any moment which amendments affect the file.

5. Verification checklist

• □ Confirmed that the current rules are MDR 2017 (gazetted 2018-01-16)
• □ Checked the applicable S.R.O. amendment numbers
• □ Distinguished the rule body from the schedules (Schedule B / C)
• □ Confirmed the product grouping position (Schedule B)
• □ Confirmed the current fee position (Schedule C)

Regulatory information verified as of 28 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across South Asia, including Pakistan. Our team prepares dossiers to DRAP expectations, manages eCTD-format submissions and deficiency responses, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com